Luis E. Raez, MD

Dr. Grivas confirms ctDNA integration into multidisciplinary tumor boards is increasing, describing his bladder cancer multidisciplinary clinic involving urology, medical oncology, radiation oncology, and pathology/radiology review focused on localized muscle-invasive bladder cancer.

Dr. Weinberg explains the treatment on molecular recurrence (TOMR) concept, drawing parallels to biochemical relapse monitoring in prostate cancer. In colorectal cancer, patients with positive ctDNA after completing curative-intent surgery and adjuvant chemotherapy will experience radiographic recurrence at a median of approximately 5.5 months, representing a population potentially amenable to curative intervention through escalated imaging to identify oligometastatic disease suitable for metastasectomy, or enrollment in novel drug development trials.

Dr. Teplinsky addresses where ctDNA and MRD testing fit within the patient care continuum, noting that value isn't uniform across disease stages or tumor types. The strongest signal currently exists in the post-treatment surveillance setting, where tumor-informed assays can identify patients at higher recurrence risk before disease becomes visible on imaging.

Dr. John Strickler introduces the program on circulating tumor DNA (ctDNA) and minimal residual disease (MRD) testing across solid tumors, joined by Dr. Eleonora Teplinsky (breast and gynecologic oncology, Valley Health System), Dr. Ben Weinberg (gastrointestinal oncology, Georgetown University), Dr. Petros Grivas (genitourinary oncology, Fred Hutchinson Cancer Center), and Dr. Luis Raez (thoracic oncology, Memorial Healthcare System).

Luis E. Raez, MD, FACP, FCCP, discusses the significance of the FDA approval of repotrectinib in solid tumors harboring an NTRK gene fusion.

Closing out their discussion on biomarker testing and targeted therapies in non–small cell lung cancer, the panel of expert oncologists share clinical pearls and thoughts on the evolving treatment landscape.

Julie R. Brahmer, MD, details emerging targets in non–small cell lung cancer and the outlook for the future of treatment.

The focus turns to therapeutic strategies for treating MET exon 14 non–small cell lung cancer.

Experts on non–small cell lung cancer share their approaches to treating patients who have RET fusions and review updates on selpercatinib and pralsetinib.

Julie R. Brahmer, MD, and Joshua K. Sabari, MD, review recent data on entrectinib and larotrectinib for the treatment of patients with NSCLC with NTRK fusions.

The expert panel discusses factors that influence treatment decisions when choosing appropriate therapy for patients with ALK-rearranged NSCLC.

Experts on non–small cell lung cancer discuss recent data on brigatinib and lorlatinib for the treatment of patients with ALK rearrangements.

Luis Raez, MD, offers insights on how co-mutations in STK11 or KEAP1 impact the use of immunotherapies in KRAS G12C–mutant non–small cell lung cancer.

Joshua K. Sabari, MD, discusses adagrasib as a treatment of patients with NSCLC with KRAS G12C mutations, and provides insight on treating patients who have progressed on prior KRAS G12C inhibitors.

Expert panelists review the CodeBreaK trials focused on sotorasib in the treatment of patients with KRAS G12C-mutant non–small cell lung cancer.

Shared insight on the use of first-generation EGFR tyrosine kinase inhibitors and the role of immunotherapy in treating patients with NSCLC with uncommon EGFR mutations.

Julie R. Brahmer, MD, discusses treatment considerations when choosing between afatinib and osimertinib in patients with NSCLC with rare EGFR mutations.

Key opinion leaders on non–small cell lung cancer review treatment options for patients with EGFR mutations.

Experts on non–small cell lung cancer discuss strategies to improve molecular testing and opportunities for community physicians to reach out to expert oncologists for clinical insights.

Antonia Sepulveda, MD, PhD, an expert on NSCLC, outlines discrepancies in molecular testing between academic and community settings.

Focused discussion on tissue testing and the effect of turnaround time on NSCLC treatment and molecular testing strategies.

Expert oncologists compare the logistics and sensitivities of liquid and tissue biopsies in the treatment of non–small cell lung cancer.

A panel of experts on the treatment of non–small cell lung cancer (NSCLC) discuss the role of biomarker testing and review testing strategies.

Luis E. Raez, MD, discusses how findings from the phase 2 NADIM II trial inform the neoadjuvant treatment paradigm in non–small cell lung cancer.

Luis E. Raez, MD, discusses the clinical implications of the phase 3 KEYNOTE-024 trial in non–small cell lung cancer.

Luis E. Raez, MD, discusses the impact of PD-L1 status on immunotherapy outcomes for patients with non–small cell lung cancer.

Luis E. Raez, MD, discusses the potential utility of cemiplimab-rwlc in non–small cell lung cancer.

Luis E. Raez, MD, discusses the safety measures that have been put in place at Memorial Cancer Institute in response to the coronavirus disease 2019 (COVID-19) in lung cancer.

Luis E. Raez, MD, discusses how the COVID-19 pandemic has impacted the treatment of patients with lung cancer.

Luis E. Raez, MD, discusses the role of liquid biopsies in newly diagnosed patients with lung cancer.